Turkmenistan Mandatory State Registration: Red Lines for Medical Devices

1. Key takeaways

The mandatory registration red line in Turkmenistan is built from two layers of wording:

• The provision of Law No. 319-V on the purpose of national registration: to prevent medicines and medical devices that may endanger life and health, as well as human genetics, from being imported into Turkmenistan, produced and circulated;
• The prevailing statement at the regime level: medicines and medical devices may only be approved for use in Turkmenistan after national registration is completed; placing a device on the market or putting it into operation requires national registration as a precondition.

At the circulation level, an unregistered product must not complete any of the following five actions: customs clearance, storage, distribution, sale, and use in medical institutions.

2. Legal basis

3. Expert insights

Insight 1: putting into operation sits alongside placing on the market, extending the red line to the point of use.

The statute and the regime-level statements contain both placing on the market and putting into operation. This is not merely a prohibition on selling: it also prohibits installing a device in a hospital and starting to use it. For large equipment (imaging, laboratory, radiotherapy), this is especially critical: if the equipment has arrived on site but national registration has not been obtained, not even commissioning and start-up is permitted.

Insight 2: the five prohibited actions cover the complete chain from the border crossing to the ward.

Customs clearance, then storage, then distribution, then sale, then use in medical institutions — all five steps are prohibited in sequence, which means there is no room for an arrangement of goods first, certificate later. This is fundamentally different from markets that allow customs release followed by supplementary registration. Tender and delivery planning must therefore treat the registration certificate as a gating document: no certificate, no shipment, no installation date.

Insight 3: the first enforcer of this red line sits at the border.

Because import is expressly listed among the prohibited activities, customs is the first enforcer of the red line. In practice, the national registration certificate is checked at customs clearance; as explained in Article 36 of this series, clearance also requires handling the parallel track of mandatory TDS certification.

Insight 4: the four exemption categories are the only lawful exit from this red line.

Law No. 319-V simultaneously provides for four categories of imported devices exempt from national registration: samples imported for registration purposes (not exceeding 10 packages), products for preclinical and clinical research, exhibition items not intended for sale or subsequent use, and products for personal use. These four are not discretionary waivers but statutory exemption categories; Article 05 of this series examines each of them.

Insight 5: the red line and TDS certification are two separate tracks — do not conflate them.

National registration settles whether a product may be used as a medical product; mandatory TDS certification settles whether it conforms to Turkmen national standards. The two run in parallel and do not substitute for each other: obtaining the registration certificate does not remove the certification obligation, and vice versa. In practice, both files draw on the same core document set wherever possible, but the two confirmations and the two timelines are never merged into one approval.

4. Practical recommendations

1. Complete national registration before shipping; do not use any variant of ship first, register later.
2. Make registration a precondition in contract and logistics terms, writing the registration certificate into the contract as a condition of delivery.
3. For large equipment projects, include the putting-into-operation milestone in the schedule, and never treat the arrival date as the usable date.
4. Start mandatory TDS certification in parallel, to avoid getting stuck at customs clearance after registration is completed.
5. For products sent to exhibitions, prepare the exhibition-item documentation and retain written evidence that they are not intended for sale or subsequent use.

5. Verification checklist

• □ It is confirmed that the product has completed national registration before shipment is arranged.
• □ The contract lists the registration certificate as a condition of delivery.
• □ The schedule for large equipment projects includes the putting into operation milestone.
• □ Mandatory TDS certification has been started in parallel with national registration.
• □ Exhibition items are covered by a written statement of no intention to sell or use subsequently.

Regulatory information verified as of October 30, 2026. The content cited in this document was checked against Law No. 319-V on Drug Provision (January 12, 2016) on the purpose of national registration and the preconditions for placing devices on the market and putting them into operation, and against the Regulation on the State Registration of Medicines and Medical Devices approved by the Ministry of Health; the five prohibited actions at clearance and circulation derive from the prevailing regime-level statements of the purpose of this law, subject to the current official text.

GRZAN support in Turkmenistan: GRZAN provides registration support to manufacturers, importers and authorized representatives for this market. Local resources can be coordinated, including licensed importing entities and authorized representative arrangements, covering national registration submission, the consular legalization chain for documents, delivery of samples, alignment with mandatory TDS certification, and customs clearance support. Service capabilities include classification judgment, selection of the registration pathway, preparation of dossiers in the national format, notarization and consular legalization, preparation of testing and stability documentation, organization of GMP and ISO 13485 evidence, variations and renewal, and vigilance and post-market maintenance. Contact: info@grzanglobal.com.